BIOMARIN PHARMACEUTICAL INC (BMRN) Fundamental Analysis & Valuation

NASDAQ:BMRN • US09061G1013

Current stock price

58.51 USD
-0.56 (-0.95%)
At close:
58.51 USD
0 (0%)
After Hours:

This BMRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BMRN Profitability Analysis

1.1 Basic Checks

  • In the past year BMRN was profitable.
  • In the past year BMRN had a positive cash flow from operations.
  • BMRN had positive earnings in 4 of the past 5 years.
  • BMRN had a positive operating cash flow in each of the past 5 years.
BMRN Yearly Net Income VS EBIT VS OCF VS FCFBMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 4.59%, BMRN belongs to the top of the industry, outperforming 90.93% of the companies in the same industry.
  • BMRN has a better Return On Equity (5.73%) than 90.73% of its industry peers.
  • The Return On Invested Capital of BMRN (9.64%) is better than 94.02% of its industry peers.
  • BMRN had an Average Return On Invested Capital over the past 3 years of 6.29%. This is significantly below the industry average of 19.44%.
  • The last Return On Invested Capital (9.64%) for BMRN is above the 3 year average (6.29%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.59%
ROE 5.73%
ROIC 9.64%
ROA(3y)4.38%
ROA(5y)2.86%
ROE(3y)5.55%
ROE(5y)3.65%
ROIC(3y)6.29%
ROIC(5y)N/A
BMRN Yearly ROA, ROE, ROICBMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 -20

1.3 Margins

  • BMRN's Profit Margin of 10.83% is amongst the best of the industry. BMRN outperforms 90.93% of its industry peers.
  • BMRN's Profit Margin has declined in the last couple of years.
  • BMRN has a better Operating Margin (27.06%) than 95.56% of its industry peers.
  • In the last couple of years the Operating Margin of BMRN has grown nicely.
  • BMRN has a better Gross Margin (81.43%) than 85.14% of its industry peers.
  • BMRN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 27.06%
PM (TTM) 10.83%
GM 81.43%
OM growth 3Y106.3%
OM growth 5YN/A
PM growth 3Y17.04%
PM growth 5Y-25.17%
GM growth 3Y1.91%
GM growth 5Y2.54%
BMRN Yearly Profit, Operating, Gross MarginsBMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BMRN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BMRN is still creating some value.
  • The number of shares outstanding for BMRN has been increased compared to 1 year ago.
  • The number of shares outstanding for BMRN has been increased compared to 5 years ago.
  • BMRN has a better debt/assets ratio than last year.
BMRN Yearly Shares OutstandingBMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
BMRN Yearly Total Debt VS Total AssetsBMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 5.82 indicates that BMRN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of BMRN (5.82) is better than 74.71% of its industry peers.
  • BMRN has a debt to FCF ratio of 0.83. This is a very positive value and a sign of high solvency as it would only need 0.83 years to pay back of all of its debts.
  • The Debt to FCF ratio of BMRN (0.83) is better than 94.98% of its industry peers.
  • A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
  • BMRN has a Debt to Equity ratio of 0.10. This is in the lower half of the industry: BMRN underperforms 61.97% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.83
Altman-Z 5.82
ROIC/WACC1.13
WACC8.52%
BMRN Yearly LT Debt VS Equity VS FCFBMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

  • BMRN has a Current Ratio of 5.21. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
  • BMRN has a Current ratio (5.21) which is in line with its industry peers.
  • BMRN has a Quick Ratio of 3.50. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
  • BMRN has a Quick ratio (3.50) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.21
Quick Ratio 3.5
BMRN Yearly Current Assets VS Current LiabilitesBMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BMRN Growth Analysis

3.1 Past

  • BMRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.46%.
  • BMRN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.11% yearly.
  • The Revenue has grown by 12.87% in the past year. This is quite good.
  • Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 11.60% on average per year.
EPS 1Y (TTM)-19.46%
EPS 3Y83.09%
EPS 5Y-17.11%
EPS Q2Q%-137.5%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y15.4%
Revenue growth 5Y11.6%
Sales Q2Q%17.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 41.22% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, BMRN will show a quite strong growth in Revenue. The Revenue will grow by 11.79% on average per year.
EPS Next Y162.78%
EPS Next 2Y77.74%
EPS Next 3Y58.77%
EPS Next 5Y41.22%
Revenue Next Year12.65%
Revenue Next 2Y12.03%
Revenue Next 3Y12.71%
Revenue Next 5Y11.79%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BMRN Yearly Revenue VS EstimatesBMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
BMRN Yearly EPS VS EstimatesBMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

8

4. BMRN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 32.87, which means the current valuation is very expensive for BMRN.
  • 92.08% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
  • BMRN's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.71.
  • BMRN is valuated correctly with a Price/Forward Earnings ratio of 12.51.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 96.91% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of BMRN to the average of the S&P500 Index (23.83), we can say BMRN is valued slightly cheaper.
Industry RankSector Rank
PE 32.87
Fwd PE 12.51
BMRN Price Earnings VS Forward Price EarningsBMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 96.14% of the companies in the same industry are more expensive than BMRN, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, BMRN is valued cheaper than 96.53% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.69
EV/EBITDA 10.55
BMRN Per share dataBMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of BMRN may justify a higher PE ratio.
  • A more expensive valuation may be justified as BMRN's earnings are expected to grow with 58.77% in the coming years.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y77.74%
EPS Next 3Y58.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BMRN Dividend Analysis

5.1 Amount

  • No dividends for BMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BMRN Fundamentals: All Metrics, Ratios and Statistics

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (3/13/2026, 8:12:13 PM)

After market: 58.51 0 (0%)

58.51

-0.56 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23
Earnings (Next)04-29
Inst Owners100.79%
Inst Owner Change4.8%
Ins Owners0.67%
Ins Owner Change-1.05%
Market Cap11.25B
Revenue(TTM)3.22B
Net Income(TTM)348.90M
Analysts81.25
Price Target92.49 (58.08%)
Short Float %4.5%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-139.93%
Min EPS beat(2)-142.18%
Max EPS beat(2)-137.68%
EPS beat(4)2
Avg EPS beat(4)-50.99%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)-11.67%
EPS beat(12)8
Avg EPS beat(12)-5.02%
EPS beat(16)11
Avg EPS beat(16)-18.07%
Revenue beat(2)1
Avg Revenue beat(2)0.52%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)3.57%
Revenue beat(4)2
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)5
Avg Revenue beat(8)2.04%
Revenue beat(12)6
Avg Revenue beat(12)0.83%
Revenue beat(16)8
Avg Revenue beat(16)0.27%
PT rev (1m)-1.94%
PT rev (3m)-0.51%
EPS NQ rev (1m)-18.95%
EPS NQ rev (3m)-21.48%
EPS NY rev (1m)5.5%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)-6.66%
Revenue NQ rev (3m)-5.61%
Revenue NY rev (1m)2.73%
Revenue NY rev (3m)4.88%
Valuation
Industry RankSector Rank
PE 32.87
Fwd PE 12.51
P/S 3.49
P/FCF 15.69
P/OCF 13.59
P/B 1.85
P/tB 1.98
EV/EBITDA 10.55
EPS(TTM)1.78
EY3.04%
EPS(NY)4.68
Fwd EY7.99%
FCF(TTM)3.73
FCFY6.37%
OCF(TTM)4.31
OCFY7.36%
SpS16.75
BVpS31.65
TBVpS29.52
PEG (NY)0.2
PEG (5Y)N/A
Graham Number35.6
Profitability
Industry RankSector Rank
ROA 4.59%
ROE 5.73%
ROCE 12.75%
ROIC 9.64%
ROICexc 12.49%
ROICexgc 13.54%
OM 27.06%
PM (TTM) 10.83%
GM 81.43%
FCFM 22.26%
ROA(3y)4.38%
ROA(5y)2.86%
ROE(3y)5.55%
ROE(5y)3.65%
ROIC(3y)6.29%
ROIC(5y)N/A
ROICexc(3y)7.4%
ROICexc(5y)N/A
ROICexgc(3y)8.13%
ROICexgc(5y)N/A
ROCE(3y)8.32%
ROCE(5y)N/A
ROICexgc growth 3Y117.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y120.08%
ROICexc growth 5YN/A
OM growth 3Y106.3%
OM growth 5YN/A
PM growth 3Y17.04%
PM growth 5Y-25.17%
GM growth 3Y1.91%
GM growth 5Y2.54%
F-Score6
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.83
Debt/EBITDA 0.63
Cap/Depr 139.49%
Cap/Sales 3.45%
Interest Coverage 120.32
Cash Conversion 87.04%
Profit Quality 205.51%
Current Ratio 5.21
Quick Ratio 3.5
Altman-Z 5.82
F-Score6
WACC8.52%
ROIC/WACC1.13
Cap/Depr(3y)114.54%
Cap/Depr(5y)116.58%
Cap/Sales(3y)3.77%
Cap/Sales(5y)4.81%
Profit Quality(3y)115.9%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.46%
EPS 3Y83.09%
EPS 5Y-17.11%
EPS Q2Q%-137.5%
EPS Next Y162.78%
EPS Next 2Y77.74%
EPS Next 3Y58.77%
EPS Next 5Y41.22%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y15.4%
Revenue growth 5Y11.6%
Sales Q2Q%17.03%
Revenue Next Year12.65%
Revenue Next 2Y12.03%
Revenue Next 3Y12.71%
Revenue Next 5Y11.79%
EBIT growth 1Y53.85%
EBIT growth 3Y138.08%
EBIT growth 5YN/A
EBIT Next Year63.85%
EBIT Next 3Y28.51%
EBIT Next 5Y24.75%
FCF growth 1Y50.82%
FCF growth 3Y152.76%
FCF growth 5YN/A
OCF growth 1Y44.54%
OCF growth 3Y67.59%
OCF growth 5Y57.51%

BIOMARIN PHARMACEUTICAL INC / BMRN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to BMRN.


What is the valuation status for BMRN stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.


Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?

BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 8 / 10.


What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.


What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 162.78% in the next year.